Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease.
cirrhosis
hepatitis E
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
02
04
2020
revised:
22
09
2020
accepted:
28
09
2020
pubmed:
11
10
2020
medline:
11
10
2020
entrez:
10
10
2020
Statut:
ppublish
Résumé
In most immune-competent individuals, hepatitis E (HEV) infections appear silent. It is unclear whether past HEV infections deteriorate disease severity in patients with non-alcoholic fatty liver disease (NAFLD). Patients with biopsy-proven NAFLD and data on anti-HEV immunoglobulin M (HEV-IgM) and anti-HEV IgG antibodies (HEV-IgG) were included. The NAFLD activity score (NAS) was used to grade and stage all liver biopsy samples. The HEV-IgG prevalence was compared to a healthy cohort of 997 subjects. One hundred sixty-seven patients with NAFLD were included with the following characteristics: age, 50 ± 13 years; NAS ≤4, 89 (53.3%); NAS 5-8, 78 (46.7%); cirrhosis, 16 (9.6%). Two patients (1.2%) were HEV-IgM-positive, however HEV polymerase chain reaction remained negative and no signs of acute hepatitis were seen. Forty-four patients (26.3%) were HEV-IgG-positive and they were significantly older (55 ± 10 years vs. 48 ± 13 years, P < 0.001) and predominantly men (31 [70.5%] vs.13 [29.5%], P = 0.022). Distribution across NAS (P = 0.610) was not different. However, HEV-IgG-positive patients were significantly more often found with cirrhosis (8 [18.2%] vs. 8 [6.5%], P = 0.024) and liver stiffness values >10 kPa (14 [58.2%] vs. 29 [43.3%], P = 0.026). Multivariable analyses revealed age (odds ratio [OR], 1.054 [1.022-1.086]) and male sex (OR 2.77 [1.27-6.04]) associated with HEV-IgG positivity. Presence of diabetes (OR 3.86 [1.18-12.59]), higher aspartate aminotransferase levels (OR, 1.02 [1.006-1.033]), and HEV-IgG seropositivity (OR 3.52 [1.11-11.13]) were independently linked to cirrhosis. Finally, HEV-IgG positivity was not independently associated with NAFLD patients in a case-control study including healthy subjects. Prevalence of anti-HEV-IgG antibodies in patients with NAFLD is linked to age and male sex. Furthermore, previous HEV infection was an independent risk factor for cirrhosis. Whether this finding is causal or solely associative is unclear and should be elucidated in future studies.
Types de publication
Journal Article
Langues
eng
Pagination
69-79Informations de copyright
© 2020 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
Références
European Association for the Study of the Liver. Clinical practice guidelines on hepatitis E virus infection. J Hepatol 2018; 68: 1256-1271.
Westholter D, Hiller J, Denzer U et al. HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. J Hepatol 2018; 69: 36-42.
Kamar N, Izopet J, Pavio N et al. Hepatitis E virus infection. Nat Rev Dis Primers 2017; 3: 17086.
Faber M, Willrich N, Schemmerer M et al. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J Viral Hepat 2018; 25: 752-758.
Lagler H, Poeppl W, Winkler H et al. Hepatitis E virus seroprevalence in Austrian adults: a nationwide cross-sectional study among civilians and military professionals. PloS One 2014; 9: e87669.
Alberts CJ, schim van der Loeff MF, Sadik S et al. Hepatitis E virus seroprevalence and determinants in various study populations in the Netherlands. PloS One 2018; 13: e0208522.
Nanji AA, French SW. Relationship between pork consumption and cirrhosis. Lancet 1985; 1(8430): 681-683.
Dalton HR, Bendall RP, Pritchard C, Henley W, Melzer D. National mortality rates from chronic liver disease and consumption of alcohol and pig meat. Epidemiol Infect 2010; 138: 174-182.
Schulz M, Beha D, Plehm K, Zöllner C, Hofmann J, Schott E. High prevalence of anti-hepatitis E virus antibodies in outpatients with chronic liver disease in a university medical center in Germany. Eur J Gastroenterol Hepatol 2016; 28: 1431-1436.
Eder M, Strassl R, Beinhardt S et al. High seroprevalence of anti-hepatitis E antibodies in Austrian patients with autoimmune hepatitis. Liver Int 2019; 39: 640-645.
Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20.
Traussnigg S, Kienbacher C, Halilbasic E et al. Challenges and management of liver cirrhosis: practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH. Dig Dis 2015; 33: 598-607.
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018; 68: 335-352.
Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol 2018; 68: 1239-1246.
Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
Schnegg A, Burgisser P, Andre C et al. An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PloS One 2013; 8: e62980.
Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010; 82: 799-805.
Blasco-Perrin H, Madden RG, Stanley A et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Aliment Pharmacol Ther 2015; 42: 574-581.
Teshale EH, Hu DJ. Hepatitis E: epidemiology and prevention. World J Hepatol 2011; 3(12): 285-291.
Doceul V, Bagdassarian E, Demange A, Pavio N. Zoonotic hepatitis E virus: classification, animal reservoirs and transmission routes. Viruses 2016; 8(10): 270.
Prattala R, Paalanen L, Grinberga D, Helasoja V, Kasmel A, Petkeviciene J. Gender differences in the consumption of meat, fruit and vegetables are similar in Finland and the Baltic countries. Eur J Public Health 2007; 17: 520-525.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717.
Mansuy JM, Bendall R, Legrand-Abravanel F et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 2011; 17: 2309-2312.
Stefanidis I, Zervou EK, Rizos C et al. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. Int J Artif Organs 2004; 27: 842-847.
Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
Noureddin M, Yates KP, Vaughn IA et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013; 58: 1644-1654.
Riveiro-Barciela M, Buti M, Homs M et al. Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection. PloS One 2014; 9: e103028.
Kumar Acharya S, Kumar Sharma P, Singh R et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46: 387-394.
Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol 2014; 20: 2564-2577.
Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014; 61: 1385-1396.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab Clin Exp 2016; 65: 1038-1048.